Table 5. Meta-analysis of the association of albumin and CRP with AVF stenosis and thrombosis.
| AVF Outcome | Biomarker | Studies | NCases | NControls | SMD (95%CI) | p value* | I2 | I2 p-value |
|---|---|---|---|---|---|---|---|---|
| Stenosis | Albumin | 7 | 257 | 311 | -0.24 [-0.57, 0.08] | 0.14 | 71% | 0.002 |
| Albumin† | 6 | 246 | 277 | -0.14 [-0.42, 0.15] | 0.34 | 60% | 0.03 | |
| CRP | 5 | 201 | 210 | 0.19 [-0.14, 0.52] | 0.26 | 61% | 0.04 | |
| CRP† | 4 | 190 | 176 | 0.06 [-0.15, 0.26] | 0.59 | 0% | 0.44 | |
| Thrombosis | Albumin | 3 | 90 | 126 | -0.53 [-1.14, 0.08] | 0.09 | 77% | 0.01 |
| CRP | 4 | 150 | 207 | 0.27 [-0.08, 0.62] | 0.13 | 57% | 0.07 | |
| CRP† | 3 | 139 | 173 | 0.12 [-0.10, 0.34] | 0.30 | 0% | 0.83 |
SMD: standardised mean difference; I2: heterogeneity index; CRP: C-reactive protein; NCases: Number of patients with a failed AVF; NControls: Number of patients with a patent AVF
*Calculated according to inverse-variance random-effects model
†Analysis excluded mixed population data from Bojakowski et al. P-values in bold are significant.